Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955586 | 1.00 | CTSK (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL31127632 | 0.91 | CTSK (0.54) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL3378240 | 0.87 | CTSK (0.48) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL3386138 | 0.87 | CTSK (0.48) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9911449 | 0.85 | CA1 (0.52) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL5196572 | 0.85 | CTSK (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL21972768 | 0.85 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL3378245 | 0.84 | CTSK (0.55) | CTSKCTSS | |
| SCHEMBL24387777 | 0.83 | AAK1 (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL22960729 | 0.83 | CTSK (0.48) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-8759365-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-8759365-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-8759365-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| EP-2404901-A1 | 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | Novartis AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| EP-2404901-A1 | 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | Novartis AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| EP-2229356-B1 | 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-20100311750-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311750-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311750-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311750-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CTSK 684/4885CTSS 356/4885CA1 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.